Intensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management in Patients With Renal Cell Carcinoma

Adverse events (AEs) with Cabozantinib are frequent (about 40-67% of patients) and often lead to temporary treatment interruptions, dose reductions or permanent discontinuations, potentially reducing dose intensity and sustained exposure. Therefore, strategies are needed to improve tolerability without compromising antitumor activity. Therapeutic drug monitoring (TDM) is particularly suitable for drugs with high interpatient variability, narrow therapeutic windows and defined exposure-response relationships; real world data support this profile for Cabozantinib and suggest that pharmacokinetic

Trial Details

NCT ID
NCT07805122
Phase
NA
Sponsor
Centro di Riferimento Oncologico - Aviano
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Intensified Monitoring of Pharmacology
Locations (sample)
  • Aviano, Pordenone, Italy|46.07056,12.59472

Key Eligibility Criteria

  • Patients diagnosed with histologically confirmed advanced/metastatic RCC with predominantly clear cell subtype.
  • Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCC, candidate to receive systemic treatment with ni…
  • Signed Written Informed Consent.
  • Male or female subjects aged ≥18 years old.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →